IBI363
- Generic Name
- IBI363
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06797297
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Jishuitan Hospital, Capital Medical University, Beijing, Beijing, China
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 296
- Registration Number
- NCT06620822
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of IBI363 in Patients with Advanced First-line Gastric Cancer
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Xiangdong Cheng
- Target Recruit Count
- 40
- Registration Number
- NCT06610799
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of IBI363 in Subjects with Advanced Solid Malignancies
- Conditions
- MelanomaNon-small Cell Lung CancerColorectal CancerRenal Cell Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 178
- Registration Number
- NCT06281678
- Locations
- 🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸Ocala Oncology Center, Ocala, Florida, United States
🇺🇸BRCR Medical Center, Plantation, Florida, United States
The Efficacy and Safety of IBI363 in Solid Tumors
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 430
- Registration Number
- NCT06081907
- Locations
- 🇨🇳
Yongchang Zhang, Changsha, Hunan, China
A Study of IBI363 in Subjects With Advanced Melanoma
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06081920
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The Third people's hospital of Zhengzhou, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05290597
- Locations
- 🇦🇺
Kate.Wilkinson1@health.nsw.gov.au, Sydney, New South Wales, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺Sydney Southwest Private Hospital, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.